TRAIL

TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) is a protein that is produced and secreted by most normal tissue cells. It has been shown to induce apoptosis in tumor cells and is being investigated for its potential as a cancer therapy.

Function

TRAIL is a member of the tumor necrosis factor (TNF) family of ligands which can induce apoptosis through the activation of its receptors, DR4 and DR5. The process of apoptosis is an important mechanism to maintain cellular homeostasis and to eliminate cells that are damaged, infected or transformed. TRAIL has been shown to selectively kill cancer cells without affecting normal cells, making it a promising candidate for cancer therapy.

Structure

The TRAIL protein is a type II transmembrane protein, which means it is anchored in the cell membrane with its functional domain facing the outside of the cell. It is composed of 281 amino acids and has a molecular weight of approximately 32.5 kDa. The protein can also be cleaved to form a soluble version that can bind to its receptors.

Clinical significance

TRAIL has been shown to induce apoptosis in a variety of cancer cell lines, including breast, colon, lung, and prostate cancer. This has led to the development of several TRAIL-based therapies that are currently being tested in clinical trials. However, some cancer cells have been found to be resistant to TRAIL-induced apoptosis, which is a major challenge for the use of TRAIL as a cancer therapy.

See also

• Apoptosis
• Tumor necrosis factor
• DR4
• DR5